Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.

The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.

Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.

By accessing this website you accept this legal notice and expressly confirm your status as a healthcare professional.

Meet the Experts
Date and time:
28.09.2021 at 09:15 - 09:45 CEST
Corporate Event
Filip Knop; Vanita Aroda;
European Association for the Study of Diabetes (EASD)
Industry session on the occasion of the 57th Annual Meeting of the European Association for the Study of Diabetes. Diabetes is a chronic disease characterised by hyperglycaemia, ultimately leading to microvascular (retinopathy, nephropathy, neuropathy) damage and to macrovascular (atherosclerotic ischaemic) events like myocardial infarction, cerebrovascular events, and complications related to peripheral vascular disease. The number of patients with diabetes and its proportion relative to the overall population is rising worldwide. Novel antihyperglycemic class glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been available for use since 2005, and yet, despite their good fit with goals of treatment, their use and broader accessibility has been limited by their availability only as an injection. And we now have the first ever oral GLP-1 RA for treatment of type 2 diabetes (T2D) approved for clinical use, which has been comprehensively studied in the PIONEER clinical trial programme. Incorporation of oral semaglutide may advance multiple care goals for patients with T2D, including achievement of glycemic goals, lifestyle and weight management goals. Novo Nordisk is pleased to introduce an industry session (Meet-the-expert) on “Oral semaglutide: Where and how does it fit?”. This session aims to present the efficacy, safety and tolerability profile of oral semaglutide from the PIONEER trials. For this session, we are delighted to welcome Prof. Filip K Knop and Dr. Vanita Aroda who will start the session with an overview of oral semaglutide and PIONEER trials followed by conversations using clinical case-based scenarios to discuss where- and how- oral semaglutide fits in patients with early/established/advanced T2D. Further to this, Dr. Vanita Aroda will take us through patient-centric practicalities of prescribing oral semaglutide in patients with T2D. The session will conclude with a live panel discussion, allowing the audience to engage with the faculty during a question and answer session. Please join us virtually on 28 Sep 2021, 09:15- 09:45 CEST to learn about oral semaglutide: where and how does it fit?

Overview of oral semaglutide and PIONEER trials

Case scenarios based on clinical evidence

Patient-centric practicalities

A patient-centered approach with oral semaglutide

Filip Krag Knop - Speaker

Filip Krag Knop

University of Copenhagen, Copenhagen, Denmark

Filip K. Knop, MD PhD, is a professor of endocrinology and director of Center for Clinical Metabolic Research at Gentofte Hospital, University of Copenhagen, and consultant endocrinologist at Steno Diabetes Center Copenhagen. Prof. Knop has been involved in diabetes and metabolic research since his fellowship at The Distinguished Gifford Laboratories for Diabetes Research, University of Texas, Southwestern Medical Center in Dallas in 1999 (supervised by Christopher B. Newgard). Knop received his MD degree in 2002 and his PhD in medical sciences in 2007 from University of Copenhagen (supervisor: Jens J. Holst). Knop’s research centres on human metabolism, the pathophysiology of obesity and related disorders including type 2 diabetes and non-alcoholic fatty liver disease, regulation of appetite and food intake, and the therapeutic potential of factors involved in these processes. The Knop laboratory has reported several novel findings describing the integrative role of the gut and the liver in human (patho)physiology. 


Prof. Knop has authored 378 peer-reviewed scientific publications and he has received several honours for his research (e.g. named “Rising star” by the European Association for the Study of Diabetes (EASD) in 2010, the DPLU/LUDC Nordic Prize for an Outstanding Young Diabetes Investigator (2011), Johan Quentin and Wife’s Prize for Outstanding Research (2014), The Capital Region of Denmark’s Global Excellence Prize (2014), The Thomsen Prize (2015), The Niels Schwartz Sørensen Prize (2017), The Danish Odd Fellowship’s Research Prize (2017), the European Journal of Endocrinology Prize 2018, and EASD’s Minkowski Prize 2019). He serves as a referee for several international journals including The Lancet, British Medical Journal, Diabetes and Diabetologia and he is a member of numerous professional societies and committees.

Read full bio
Vanita R. Aroda - Speaker

Vanita R. Aroda

Brigham and Women's Hospital, Boston, Massachusetts, USA

Vanita Aroda is the Director of Diabetes Clinical Research at the Brigham and Women's Hospital in Boston, MA, and is Member of the Faculty of Harvard Medical School. Dr. Aroda completed her training in Internal Medicine and in Endocrinology, Diabetes and Metabolism at the University of California San Diego, CA, USA.


Dr. Aroda has an interest and published record in diabetes prevention and novel therapeutics in diabetes and weight management. She also has a strong interest in understanding therapeutic interventions in large multicenter clinical trials and their applicability and integration into care. Dr. Aroda has years of experience in clinical trial conduct and leadership, has served as an investigator on the National Institutes of Health-funded GRADE, D2d, and DPPOS studies, and as the national or international signatory Principal Investigator for multiple therapeutic clinical trials. Dr. Aroda serves on the Professional Practice Committee of the American Diabetes Association.

Read full bio